Effect of anticoagulant and antiplatelet therapy in patients with spontaneous intra-cerebral hemorrhage: Does medication use predict worse outcome?

Clinical Neurology and Neurosurgery

Volumn 112, Issue 4, 2010, Pages 275-281

  Stead, Latha G ^d   Jain, Anunaya ^d   Bellolio, M Fernanda ^a   Odufuye, Adetolu O ^b   Dhillon, Ravneet K ^a   Manivannan, Veena ^a   Gilmore, Rachel M ^a   Rabinstein, Alejandro A ^c   Chandra, Raghav ^a   Serrano, Luis A ^a   Yerragondu, Neeraja ^a   Palamari, Balavani ^a   Decker, Wyatt W ^a  

^a Mayo Clinic College of Medicine   (United States)

^b MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Anticoagulants; Cerebral hemorrhage; Platelet aggregation inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; FRESH FROZEN PLASMA; HEPARIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBOCYTE CONCENTRATE; VITAMIN K GROUP; WARFARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BRAIN HEMORRHAGE; CONTROLLED STUDY; CRANIOTOMY; DISEASE SEVERITY; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; RECURRENT DISEASE; RISK FACTOR; SURGICAL DRAINAGE; THROMBOCYTE; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BRAIN; CEREBRAL HEMORRHAGE; COHORT STUDIES; DATA INTERPRETATION, STATISTICAL; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PLATELET AGGREGATION INHIBITORS; PROGNOSIS; TREATMENT OUTCOME;

EID: 77950056341     PISSN: 03038467     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clineuro.2009.12.002     Document Type: Article

References (42)

1. Lloyd-Jones D., Adams R., Carnethon M., De Simone G., Ferguson T.B., Flegal K., et al. Heart disease and stroke statistics-2009 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119 3 (2009) e21-e181
2. Hirsh J., Fuster V., Ansell J., and Halperin J.L. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol 41 9 (2003) 1633-1652
3. Connolly S. Stroke prevention in atrial fibrillation II study. Lancet 343 8911 (1994) 1509
4. Cairns J.A. Stroke prevention in atrial fibrillation trial. Circulation 84 2 (1991) 933-935
5. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 342 8882 (1993) 1255-1262
6. Holbrook A.M., Pereira J.A., Labiris R., McDonald H., Douketis J.D., Crowther M., et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 165 10 (2005) 1095-1106
7. Budnitz D.S., Shehab N., Kegler S.R., and Richards C.L. Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med 147 11 (2007) 755-765
8. Chambers M., Hutton J., and Gladman J. Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin-dipyridamole. Pharmacoeconomics 16 5 (Pt 2) (1999) 577-593
9. Engelter S., and Lyrer P. Antiplatelet therapy for preventing stroke and other vascular events after carotid endarterectomy. Cochrane Database Syst Rev 3 (2003) [CD001458]
10. Wintzen A.R., de Jonge H., Loeliger E.A., and Bots G.T. The risk of intracerebral hemorrhage during oral anticoagulant treatment: a population study. Ann Neurol 16 5 (1984) 553-558
11. Flaherty M.L., Kissela B., Woo D., Kleindorfer D., Alwell K., Sekar P., et al. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology 68 2 (2007) 116-121
12. Tuhrim S. Aspirin-use before ICH: a potentially treatable iatrogenic coagulopathy?. Stroke 37 1 (2006) 4-5
13. Steiner T., Rosand J., and Diringer M. Intracerebral hemorrhage associated with oral anticoagulant therapy: current practices and unresolved questions. Stroke 37 1 (2006) 256-262
14. Saloheimo P., Ahonen M., Juvela S., Pyhtinen J., Savolainen E.R., and Hillbom M. Regular aspirin-use preceding the onset of primary intracerebral hemorrhage is an independent predictor for death. Stroke 37 1 (2006) 129-133
15. Flibotte J.J., Hagan N., O'Donnell J., Greenberg S.M., and Rosand J. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology 63 6 (2004) 1059-1064
16. Hanger H.C., Fletcher V.J., Wilkinson T.J., Brown A.J., Frampton C.M., and Sainsbury R. Effect of aspirin and warfarin on early survival after intracerebral haemorrhage. J Neurol 255 3 (2008) 347-352
17. Aguilar M.I., Hart R.G., Kase C.S., Freeman W.D., Hoeben B.J., Garcia R.C., et al. Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. Mayo Clin Proc 82 1 (2007) 82-92
18. Kothari R.U., Brott T., Broderick J.P., Barsan W.G., Sauerbeck L.R., Zuccarello M., et al. The ABCs of measuring intracerebral hemorrhage volumes. Stroke 27 8 (1996) 1304-1305
19. Williams L.S., Yilmaz E.Y., and Lopez-Yunez A.M. Retrospective assessment of initial stroke severity with the NIH Stroke Scale. Stroke 31 4 (2000) 858-862
20. Cheung C.M., Tsoi T.H., Hon S.F., Au-Yeung M., Shiu K.L., Lee C.N., et al. Using the National Institutes of Health Stroke Scale (NIHSS) to predict the mortality and outcome of patients with intracerebral haemorrhage. Hong Kong Med J 14 5 (2008) 367-370
21. Sulter G., Steen C., and De Keyser J. Use of the Barthel index and modified Rankin scale in acute stroke trials. Stroke 30 8 (1999) 1538-1541
22. Wong K.S., Mok V., Lam W.W., Kay R., Tang A., Chan Y.L., et al. Aspirin-associated intracerebral hemorrhage: clinical and radiologic features. Neurology 54 12 (2000) 2298-2301
23. Toyoda K., Okada Y., Minematsu K., Kamouchi M., Fujimoto S., Ibayashi S., et al. Antiplatelet therapy contributes to acute deterioration of intracerebral hemorrhage. Neurology 65 7 (2005) 1000-1004
24. Sansing L.H., Messe S.R., Cucchiara B.L., Cohen S.N., Lyden P.D., and Kasner S.E. Prior antiplatelet use does not affect hemorrhage growth or outcome after ICH. Neurology 72 16 (2009) 1397-1402
25. Roquer J., Rodriguez Campello A., Gomis M., Ois A., Puente V., and Munteis E. Previous antiplatelet therapy is an independent predictor of 30-day mortality after spontaneous supratentorial intracerebral hemorrhage. J Neurol 252 4 (2005) 412-416
26. Foerch C., Sitzer M., Steinmetz H., and Neumann-Haefelin T. Pretreatment with antiplatelet agents is not independently associated with unfavorable outcome in intracerebral hemorrhage. Stroke 37 8 (2006) 2165-2167
27. Lacut K., Le Gal G., Seizeur R., Prat G., Mottier D., and Oger E. Antiplatelet drug use preceding the onset of intracerebral hemorrhage is associated with increased mortality. Fundam Clin Pharmacol 21 3 (2007) 327-333
28. Broderick J.P. Evidence against rapid reversal of antiplatelet medications in acute intracerebral hemorrhage. Neurology 72 16 (2009) 1376-1377
29. Stafford R.S., and Singer D.E. National patterns of warfarin use in atrial fibrillation. Arch Intern Med 156 22 (1996) 2537-2541
30. Fang M.C., Go A.S., Chang Y., Hylek E.M., Henault L.E., Jensvold N.G., et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med 120 8 (2007) 700-705
31. Fang M.C., Go A.S., Hylek E.M., Chang Y., Henault L.E., Jensvold N.G., et al. Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study. J Am Geriatr Soc 54 8 (2006) 1231-1236
32. Sjoblom L., Hardemark H.G., Lindgren A., Norrving B., Fahlen M., Samuelsson M., et al. Management and prognostic features of intracerebral hemorrhage during anticoagulant therapy: a Swedish multicenter study. Stroke 32 11 (2001) 2567-2574
33. Flaherty M.L., Tao H., Haverbusch M., Sekar P., Kleindorfer D., Kissela B., et al. Warfarin use leads to larger intracerebral hematomas. Neurology 71 14 (2008) 1084-1089
34. Broderick J.P., Brott T.G., Duldner J.E., Tomsick T., and Huster G. Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality. Stroke 24 7 (1993) 987-993
35. Zubkov A.Y., Mandrekar J.N., Claassen D.O., Manno E.M., Wijdicks E.F., and Rabinstein A.A. Predictors of outcome in warfarin-related intracerebral hemorrhage. Arch Neurol 65 10 (2008) 1320-1325
36. Cucchiara B., Messe S., Sansing L., Kasner S., and Lyden P. Hematoma growth in oral anticoagulant related intracerebral hemorrhage. Stroke 39 11 (2008) 2993-2996
37. Goldstein J.N., Rosand J., and Schwamm L.H. Warfarin reversal in anticoagulant-associated intracerebral hemorrhage. Neurocrit Care 9 2 (2008) 277-283
38. Huttner H.B., Schellinger P.D., Hartmann M., Kohrmann M., Juettler E., Wikner J., et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke 37 6 (2006) 1465-1470
39. Fujii Y., Takeuchi S., Sasaki O., Minakawa T., and Tanaka R. Multivariate analysis of predictors of hematoma enlargement in spontaneous intracerebral hemorrhage. Stroke 29 6 (1998) 1160-1166
40. Xi G., Wagner K.R., Keep R.F., Hua Y., de Courten-Myers G.M., Broderick J.P., et al. Role of blood clot formation on early edema development after experimental intracerebral hemorrhage. Stroke 29 12 (1998) 2580-2586
41. Hoff J.T., and Xi G. Brain edema from intracerebral hemorrhage. Acta Neurochir Suppl 86 (2003) 11-15
42. Creutzfeldt C.J., Weinstein J.R., Longstreth Jr. W.T., Becker K.J., McPharlin T.O., and Tirschwell D.L. Prior antiplatelet therapy, platelet infusion therapy, and outcome after intracerebral hemorrhage. J Stroke Cerebrovasc Dis 18 3 (2009) 221-228